参考文献/References:
[1] 麦国丰,罗荣城,马树东,等.HER2表达与乳腺癌预后的相关性研究[J].解放军医学杂志,2003,28(10):902-903.
[2] 王进,马斌林.乳腺癌 HER-2基因的表达及其临床意义[J].中国肿瘤临床与康复,2006,13(1):14-16.
[3] SLIWKOWSKI M X,LOFGREN J A,LEWIS G D,et al.Nonclinical studies addressing the mechanism of action of trastuzumab(Herceptin)[J].Semin Oncol,1999,26(4 Suppl 12):60-70.
[4] 刘敏,张璐,孙丽华,等.辽宁省肿瘤化疗患者KPS评分情况分析[J].中国肿瘤,2013(8):635-637.
[5] 张京晶,孟琼,常巍,等.肿瘤临床疗效评价研究现状与进展[J].癌症,2010,29(2):250-254.
[6] 陈丽荣,郑树.紫杉醇诱发人乳癌细胞凋亡的机制研究[J].中华肿瘤杂志,1997,19(2):103-106.
[7] MARTY M,COGNETTI F,MARANINCHI D,et al.Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:the M77001 study group[J].J Clin Oncol,2005,23(19):4265-4274.
[8] MONTEMURRO F,CHOA G,FAGGIUOLO R,et al.Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer:a pilot phase Ⅱ study[J].Am J Clin Oncol,2003,26(1):95-97.
[9] 周宁宁,林归滨,刘冬耕,等.曲托珠单抗联合多西紫杉醇治疗Her-2/neu高表达转移性乳腺癌的疗效和不良反应[J].癌症,2008,27(9):947-950.
相似文献/References:
[1]叶林华,袁苏徐.紫杉醇联合卡培他滨治疗晚期胃癌疗效观察[J].新乡医学院学报,2011,28(01):102.
[2]丁 锋,张清会.厄洛替尼联合紫杉醇和顺铂治疗晚期非小细胞肺癌疗效观察[J].新乡医学院学报,2018,35(6):513.[doi:10.7683/xxyxyxb.2018.06.016]
DING Feng,ZHANG Qing-hui.Effect of erlotinib combined with paclitaxel and cisplatin in treatment of advanced non-small cell lung cancer[J].Journal of Xinxiang Medical University,2018,35(6):513.[doi:10.7683/xxyxyxb.2018.06.016]
[3]李 果,王世进.阿帕替尼联合紫杉醇治疗复发性耐药型上皮性卵巢癌疗效观察[J].新乡医学院学报,2022,39(4):341.[doi:10.7683/xxyxyxb.2022.04.008]
LI Guo,WANG Shijin.Efficacy of apatinib combined with paclitaxel in the treatment of recurrent drug-resistant epithelial ovarian cancer[J].Journal of Xinxiang Medical University,2022,39(6):341.[doi:10.7683/xxyxyxb.2022.04.008]
[4]李小峰,孙新宇,张 慧.曲妥珠单抗联合紫杉醇和卡铂治疗人表皮生长因子受体-2阳性乳腺癌的疗效及其对心功能的影响[J].新乡医学院学报,2022,39(4):376.[doi:10.7683/xxyxyxb.2022.04.016]
LI Xiaofeng,SUN Xinyu,ZHANG Hui.Effect of trastuzumab combined with paclitaxel and carboplatin in the treatment of patients with human epidermal growth factor receptor-2-positive breast cancer and its effect on cardiac function[J].Journal of Xinxiang Medical University,2022,39(6):376.[doi:10.7683/xxyxyxb.2022.04.016]